UNSPSC 51342902: Famciclovir

This classification denotes a purine antagonist and antiviral agent with the molecular formula C14H19N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QIC03ANI02, chemically known as 1,3-propanediol, 2-(2-(2-amino-9h-purin-9-yl)ethyl)-, diacetate (ester) but generally known as famciclovir, which bears US NIH Compound Identifier 3324. European Medicines Agency schedules Famciclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07501MIG.

UNSPSC 51342902 Famciclovir is a Commodity code that encompasses individual pharmaceutical products, yet the recent state and local opportunities tagged under it show minimal alignment with this antiviral drug category—instead the opportunities cluster around broader medical supply procurement, emergency pharmaceuticals, and pharmacy benefit program administration. The issuing bodies soliciting under this code span county health systems, municipal fire departments, state health and human services agencies, and multistate cooperative purchasing organizations. What state and local governments are actually buying under the code's tagging appears to reflect general pharmaceutical and medical supply categories rather than famciclovir-specific procurement; the opportunities include emergency naloxone and drug deactivation systems, fire department first aid supplies, generic multi-source pharmaceuticals through cooperative channels, and direct-to-manufacturer pharmacy initiatives.

Recent activity shows solicitation from Seminole County, Florida (Naloxone & Drug Deactivation Systems, IFB60459723LAS, due July 26, 2023); the City of Tampa, Florida (Medical and First Aid Supplies for the Fire Department, ITB 26P00145, estimated contract value $700,000.00, response due March 13, 2026, designated as a sheltered market for certified Small Local Business Enterprises with a 5% bid discount not to exceed $10,000); the Texas Health and Human Services Commission (Request for Information on Direct-to-Manufacturer Prescriptions, RFI HHS0017013, posted April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of participating state and local government facilities in Minnesota and Oregon (Generic Multi-Source Pharmaceuticals and OTC Products, RFP S1070000015802, proposals due March 26, 2026). The geographic footprint spans Florida, Texas, Minnesota, and Oregon, with cooperative purchasing extending across multiple jurisdictions. The code shows recent activity in municipal procurement and multistate cooperative vehicles, though the tagging mismatch suggests opportunities may be miscategorized at source.